Adenosine and Ticagrelor Plasma Levels in Patients With and Without Ticagrelor-Related Dyspnea.

Ortega-Paz, Luis; Brugaletta, Salvatore; Ariotti, Sara; Akkerhuis, K Martijn; Karagiannis, Alexios; Windecker, Stephan; Valgimigli, Marco; Endotherlial function and other Circulating biomarkInvestigators, Hunting for the off-target properties of Ticagrelor on (2018). Adenosine and Ticagrelor Plasma Levels in Patients With and Without Ticagrelor-Related Dyspnea. Circulation, 138(6), pp. 646-648. Lippincott Williams & Wilkins 10.1161/CIRCULATIONAHA.118.034489

Preview	Text Ortega-Paz Circulation 2018.pdf - Accepted Version Available under License Publisher holds Copyright. Download (679kB) | Preview
	Text Ortega-Paz Circulation 2018.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (542kB)

Dyspnea is a common side effect of ticagrelor, leading to drug discontinuation in roughly one in every 20 treated patients. Studies have suggested that ticagrelor inhibits the sodium-independent equilibrative nucleoside transporter-1, which may increase adenosine plasma levels and explain drug-related dyspnea. However, the identification of a pattern of periodic breathing associated to increased chemosensitivity to hypercapnia in patients with ticagrelor-related dyspnea has reinforced the hypothesis that this side effect may result from direct inhibition of P2Y receptors on neurons leading to purinergic stimulation of the chemoreflex system. Simultaneous measurements of adenosine and ticagrelor plasma levels in patients with and without dyspnea while on treatment with ticagrelor may help unraveling the mechanism of this common and clinically relevant side effect.

Interest & Impact

Downloads

209 since deposited on 31 May 2018
18 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item